The purpose of a percutaneous coronary intervention (PCI) in coronary artery disease is to reduce symptoms and possible future events. These benefits however have not been established at length and study outcomes vary from one study to another. [1] [2] [3] [4] Chronic total occlusion (CTO) interventions as a whole have their benefit, even less well established and available literature shows conflicting results. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Moreover, technical challenges involved in CTO procedures, and the unpredictability of the result, along with limited operator expertise has precluded prospective trials. 16 The data available is therefore limited to single centre or multicentre registries only. Also, long-term outcomes post CTO intervention may depend not only on the success or failure of the CTO intervention alone but also on the completeness of revascularization, as in any other multi-vessel intervention. [17] [18] [19] [20] [21] Studies on completeness of revascularization in CTO cases are few. 22, 23 Our study therefore aimed to determine the long-term clinical outcome of CTO intervention categorizing patients with respect to both successful versus unsuccessful CTO intervention and complete (CR) versus incomplete revascularization (IR).
| METHODS
Consecutive cases where at least one CTO vessel was intervened were included in the study from January 2006 to December 2015.
CTO was defined as a coronary obstruction with thrombolysis in myocardial infarction (TIMI) flow grade 0 and estimated duration of 3 months or more. The duration of the occlusion was determined by the interval from the last episode of acute coronary syndrome (ACS) in patients with a known event, or from the time of onset of symptoms in patients without a known event, or as documented from a previous available coronary angiogram, if any. In case of CTO failure on first attempt, a second attempt was taken as per physician discretion. If successful in reattempt, the case was finally categorized as a successful CTO intervention case.
The PCI of the CTO vessel was performed using all contemporary techniques and hardware's, including specialized tapered tip dedicated CTO guide wires with increasing tip loads, single lumen, or double lumen microcatheters, parallel wire technique, and retrograde approach, when necessary. Drug eluting stents were implanted in all successful CTO cases. Standard interventional techniques were used for non-CTO lesions in patients with multivessel disease. All CTO procedures were done by a single primary operator. Post PCI, all patients were prescribed lifelong aspirin with P2Y12 inhibitors prescribed for at least 12 months. All patients were given guideline directed medical therapy (GDMT). All clinical and procedural details were recorded in a pre-specified custom-made software database as a part of usual departmental protocol, on a day-to-day basis. Follow-up data were obtained at 3 months, 6 months, and then on yearly basis as a part of a standard follow-up protocol and recorded in the same prespecified database.
| Follow-up analysis
As a part of the study, attempt was made to complete any missing follow-ups due to natural dropouts by making a telephonic contact with all such patients during a 6-month period between July 2016 to December 2016, giving an opportunity to record at-least a year followup result on the last patient included. Patients in whom not even a single follow-up was available, either on routine visits or by telephonic contact, were excluded from the study.
| DEFINITIONS
CTO was defined as a coronary obstruction with thrombolysis in myocardial infarction (TIMI) flow grade 0 and estimated duration of 3 months or more. Multivessel disease was defined as the presence of ≥70% luminal diameter stenosis in ≥2 major epicardial arteries. analysis, patients were stratified into two groups viz-"Successful"
and "Unsuccessful" CTO PCI and "Complete" or "Incomplete" revascularization groups.
| Study endpoints
The primary endpoint of the study was survival free of all adverse outcomes. Cumulative survival analyses were performed using the KaplanMeier method and the difference between curves was assessed by log-rank test.
| Statistical analysis
Follow-up was censured at the time of a repeat intervention, MI or death or the last clinical follow-up available, considering their times of occurrence only. In those without any other hard endpoint, time to occurrence of angina was used to censor the follow up. Analyses were performed using the software package SPSS 11.5 (SPSS 17 Inc., Chicago, IL).
| RESULTS
A total of 632 patients underwent CTO PCI during the study period from January 2006 to December 2015. Of these, 83 patients were excluded from the study due to non-availability of any follow-up data as per pre-defined protocol and the remaining 549 patients constituted the study cohort. Baseline characteristics of all patients included in the study are summarized in Tables 1 and 2 CTO PCI success was obtained in 490 (89%) and failure in 59 (11%)
patients. There was a total of 6 (1%) hospital deaths with two deaths in CTO success group versus four in CTo failure. Two deaths were due to guide catheter induced dissection, three due to cardiac tamponade and one due stent thrombosis.
Median follow-up of the study population was 2.9 years with interquartile range of 1.1 to 4.8 years. Maximum follow up was up to 9.8 years. Tables 3 and 4 Prior studies have shown conflicting results when evaluating longterm outcomes following CTO PCI. Some observational studies, [5] [6] [7] [8] [9] [10] [11] [12] including a meta-analysis have shown a survival benefit in successful CTO PCI group. However, a study from the Mayo Clinic and others reported no difference in 10-year mortality in CTO success versus failure groups. [13] [14] [15] In our study, there was a trend toward lower mortality in success group but it did not reach level of significance. A recently presented study, DECISION CTO, showed no difference in major adverse cardiac events at end of 3 years in patients with CTO PCI when compared to medical treatment. 16 It was the first prospective trial comparing CTO PCI versus optimised medical treatment alone. In the trial's composite primary endpoint, approximately 20% of patients Also intervening in more vessels in patients with multivessel disease turned out to be better in our cases because it not only contributed toward CR on one hand but also kept any overdo on the procedure at abeyance with our bottom line of including only vessels with >70% luminal stenosis on angiogram as a significant cut off for intervention. This is different from the usual 50% cut off used in some of the negative intervention versus medical treatment studies including COURAGE trial. 25 By virtue of above, these studies possibly included several non ischemia producing vessels to have an interventional procedure and the resulting poor or outcomes in the interventional group on long term. The same got rectified to a large extent in the FAME study with FFR based decision making. 26 Our study thus shows that completeness of revascularization could be more contributory to long-term outcomes as seen in some of the previous studies of multivessel disease irrespective of presence or absence of CTO 18-21 than CTO success or future alone.
| Clinical outcomes
The need for repeat procedure may not have been different in the two groups by either analysis viz CTO success versus failure or CR versus IR largely because of an elective acceptance of medical treatment as the alternative treatment strategy in the CTO failure group by us. This is further supported by the fact that most of the non-CTO culprit vessels had already been treated as evident by the higher mean number of vessels treated per patient in the CTO failure group and this effort in itself was probably enough to get majority of the patients asymptomatic to a large extent.
| CONCLUSION
We conclude that a successful CTO intervention is associated with a significantly better long-term combined event free survival included including mortality, MI, recurrence of angina or need for re- However, the differences in outcomes are more obvious when the same patient subset is analyzed with respect to completeness of revascularization than CTO success or failure alone.
| STUDY LIMITATIONS
Our study does have limitations. First, it is an observational study with a retrospective analysis of data although the same was recorded prospectively on a day-to-day basis with the all inherent weaknesses of any such analysis. Second, it is a single center study with all limitations/ benefits of any single center/single operator study. Further long term prospective studies are needed to assess the true clinical benefits of CTO-PCI.
